After H.C. Wainwright and Seaport Global gave Omeros Corp (NASDAQ: OMER) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy assigned a Buy rating to Omeros Corp (NASDAQ: OMER) today and set a price target of $25. The company’s shares opened today at $20.
McCarthy commented:
“Omeros announced that it has completed dosing of the first cohort of healthy subjects with OMS527, where the drug will be first evaluated for nicotine addiction.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 10.7% and a 43.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omeros Corp with a $27.25 average price target, a 36.3% upside from current levels. In a report issued on July 12, Seaport Global also initiated coverage with a Buy rating on the stock with a $30 price target.
.
See today’s analyst top recommended stocks >>
Based on Omeros Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $30.05 million. In comparison, last year the company had a GAAP net loss of $14.36 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company specializes in discovery, development, and commercializes of both small-molecule and protein therapeutics for large -market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
